Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
RNF112-mediated FOXM1 ubiquitination suppresses the proliferation and invasion of gastric cancer
Shengwei Zhang, … , Shiming Yang, Changjiang Hu
Shengwei Zhang, … , Shiming Yang, Changjiang Hu
Published June 8, 2023
Citation Information: JCI Insight. 2023;8(11):e166698. https://doi.org/10.1172/jci.insight.166698.
View: Text | PDF
Research Article Gastroenterology Oncology

RNF112-mediated FOXM1 ubiquitination suppresses the proliferation and invasion of gastric cancer

  • Text
  • PDF
Abstract

Forkhead box M1 (FOXM1) plays a critical role in development physiologically and tumorigenesis pathologically. However, insufficient efforts have been dedicated to exploring the regulation, in particular the degradation of FOXM1. Here, the ON-TARGETplus siRNA library targeting E3 ligases was used to screen potential candidates to repress FOXM1. Of note, mechanism study revealed that RNF112 directly ubiquitinates FOXM1 in gastric cancer, resulting in a decreased FOXM1 transcriptional network and suppressing the proliferation and invasion of gastric cancer. Interestingly, the well-established small-molecule compound RCM-1 significantly enhanced the interaction between RNF112 and FOXM1, which further promoted FOXM1 ubiquitination and subsequently exerted promising anticancer effects in vitro and in vivo. Altogether, we demonstrate that RNF112 suppresses gastric cancer progression by ubiquitinating FOXM1 and highlight the RNF112/FOXM1 axis serves as both prognosis biomarker and therapeutic target in gastric cancer.

Authors

Shengwei Zhang, Jing Wang, Weichao Hu, Lijiao He, Qingyun Tang, Jie Li, Mengmeng Jie, Xinzhe Li, Cheng Liu, Qin Ouyang, Shiming Yang, Changjiang Hu

×

Figure 1

Screen and identification of an E3 ligase targeting FOXM1.

Options: View larger image (or click on image) Download as PowerPoint
Screen and identification of an E3 ligase targeting FOXM1.
(A) Heatmap o...
(A) Heatmap of the fold change in endogenous FOXM1 protein expression after the transfection with siRNA targeting E3 ligases in HEK293T cells. (B) Immunoblot detection of FOXM1 in HEK293T cells after transfection with the indicated plasmids. (C) Immunoblot analysis of endogenous expression of FOXM1 and RNF112 in GES-1 cells and a panel of human gastric cancer cell lines. (D) Immunoblot analysis of endogenous FOXM1 in MGC803 and BGC823 cells after transfection with RNF112-HA plasmids and EV for 48 hours. (E) Immunoblot analysis of endogenous FOXM1 after ectopic RNF112 expression in MGC803 cells in the presence of CHX (100 μg/mL) for the indicated time. (F) Immunoblot analysis of endogenous FOXM1 expression after ectopic RNF112 expression in MGC803 and BGC823 cells treated with 10 μM MG132 for 8 hours. (G) FOXM1 and RNF112 were detected by immunoblotting in WT and RNF112-depleted MGC803 cells. (H) Immunoblot analysis of endogenous FOXM1 in WT and RNF112-depleted MGC803 cells in the presence of CHX (100 μg/mL) for the indicated time. Complete unedited blots are listed in the supplemental material.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts